Displaying 1 (all) recruiting clinical trials.
-
A Phase 2/3 Multicenter Randomized Study of Raludotatug Deruxtecan (R-DXd) a CDH6-directed Antibody-drug Conjugate in Subjects with Platinum-resistant High-grade Ovarian Primary Peritoneal or Fallopian Tube Cancer
This is a Phase 2/3 study aimed at learning more about the study medicine Raludotatug Deruxtecan (R-DXd) as a treatment for ovarian cancer patients ...
Phase
Interventional
